COMMUNIQUÉS West-GlobeNewswire

The Joint Corp. to Participate in the Lake Street Capital Markets 2019 Annual Best Ideas Growth Conference
03/09/2019
SCOTTSDALE, Ariz., Sept. 03, 2019 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, announced that management is scheduled to attend the Lake Street [...]
G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019
03/09/2019
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses will present a [...]
Trevena to Participate in Upcoming Conferences in September 2019
03/09/2019
CHESTERBROOK, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous [...]
Veta™ Smart Case & App for epinephrine auto-injectors (such as EPIPEN®) now available in Walgreens
03/09/2019
WATERLOO, Ontario, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aterica Digital Health today announces the Walgreens in-store availability of Veta™ Smart Case & App – the first-ever comprehensive anaphylaxis and food allergy [...]
Orchard Therapeutics to Webcast Presentation at the Morgan Stanley 17th Annual Global Healthcare Conference
03/09/2019
BOSTON and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life- [...]
Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test
03/09/2019
New Generation of Vision Testing Technology to be Introduced at Vision Expo West San Diego, CA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced [...]
Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda
03/09/2019
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada [...]
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
03/09/2019
Chief medical officer at Parker Institute for Cancer Immunotherapy to add immuno-oncology clinical development & industry leadership experience CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology ( [...]
MediPharm Labs Enters into Agreements with Australian Licensed Producer & Forms Multiple Cannabis Supply Partnerships to Advance Australian Market Leadership
03/09/2019
Construction of New Melbourne-area Extraction Facility on Schedule Further Strengthens Australian Leadership Team Awarded Australian Cannabis Industry 2019 Innovation Award BARRIE, Ontario, Sept. 03, 2019 (GLOBE [...]
CROSSJECT : Point d'activité : Focus sur les avancées de l'été
03/09/2019
Communiqué de Presse Point d’activité : Focus sur les avancées de l’été Dijon, le 3 septembre 2019 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un [...]
Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL
03/09/2019
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a single [...]
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
03/09/2019
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO, [...]
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
03/09/2019
Zealand Pharma company announcement – No. 29 / 2019 The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim’s pipeline portfolio in obesity and diabetes The Phase 2 trial for BI 456906 is [...]
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
03/09/2019
Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS patients and can create a substantial [...]
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
03/09/2019
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva’s novel [...]
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
03/09/2019
September 3, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Santhera Announces Financial Results for the First Half-Year 2019
03/09/2019
A conference call will be held today at 13:00 CEST, 12:00 BST, 07:00 EDT. Details are at the end of this statement. Pratteln, Switzerland, September 3, 2019 – Santhera Pharmaceuticals (SIX: SANN) reports first half-year [...]
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
03/09/2019
Basel, 3 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to [...]
Afya Limited Issues Guidance for 2nd Half of 2019
03/09/2019
On-track to Deliver 2019 Pro Forma Adjusted EBITDA above R$300 million NOVA LIMA, Brazil, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today issued guidance for results for the second half of [...]

Pages